借药明康德H股的配售,来展开聊聊这三家企业的配售策略

同壁财经
01 Aug

看到大家都在聊药明的配售到底是利空还是利好,在中概股回归与港股融资的浪潮中,H股发行定价的折价现象一直是市场关注的焦点,今天就来聊聊恒瑞医药、宁德时代与药明康德三家龙头企业近期H股配售,定价策略呈现出截然不同的市场逻辑。三家企业的定价策略对比恒瑞医药H股发行折价情况发行价格与折价率恒瑞医药H股最终发行价定为每股44.05港元(发行区间上限),较A股价格存在多维度折价:10 日均价折价:较A股过去...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10